Literature DB >> 8798431

A combinatorial library strategy for the rapid humanization of anticarcinoma BR96 Fab.

M J Rosok1, D E Yelton, L J Harris, J Bajorath, K E Hellström, I Hellström, G A Cruz, K Kristensson, H Lin, W D Huse, S M Glaser.   

Abstract

We have used a combinatorial mutagenesis strategy to humanize BR96, a monoclonal antibody that binds to the Lewis Y class of tumor antigens. This approach allows simultaneous assessment of hundreds of humanized variable regions to identify the molecules that best preserve affinity, thus overcoming the major drawback of current humanization procedures, the requirement to construct and analyze each humanized antibody separately. Murine residues of BR96 were mutated to human if they were solvent-exposed residues that did not participate in the formation of the antigen binding site and were not at the interface of the light and heavy chain. At positions that might be involved in binding to antigen, the choice between the murine and human residue was more difficult. Murine and human alternatives were incorporated into a combinatorial library at positions representing buried residues that might affect the structural integrity of the antigen binding site. By encoding this library of humanized BR96 Fabs in an M13 phage vector, we rapidly identified several candidates with nearly identical antigen binding, within 2-fold, of the chimeric Fab. Additional mutagenesis directed at sites suggested in the literature as potentially important for antigen binding in a similar anti-Lewis Y antibody yielded no further improvements.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8798431     DOI: 10.1074/jbc.271.37.22611

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

2.  High affinity mouse-human chimeric Fab against hepatitis B surface antigen.

Authors:  Biplab Bose; Navin Khanna; Subrat K Acharya; Subrata Sinha
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

3.  Generation and characterization of high affinity humanized fab against hepatitis B surface antigen.

Authors:  Ashutosh Tiwari; Durgashree Dutta; Navin Khanna; Subrat K Acharya; Subrata Sinha
Journal:  Mol Biotechnol       Date:  2009-03-27       Impact factor: 2.695

4.  A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries.

Authors:  C Rader; D A Cheresh; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

5.  Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb.

Authors:  H Wu; G Beuerlein; Y Nie; H Smith; B A Lee; M Hensler; W D Huse; J D Watkins
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

6.  Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody.

Authors:  Sanjaya Singh; Rachel R Kroe-Barrett; Keith A Canada; Xiang Zhu; Eliud Sepulveda; Helen Wu; Yaqin He; Ernest L Raymond; Jennifer Ahlberg; Lee E Frego; Laura M Amodeo; Katrina M Catron; David H Presky; Jeffrey H Hanke
Journal:  MAbs       Date:  2015-04-23       Impact factor: 5.857

Review 7.  Transgenic milk as a method for the production of recombinant antibodies.

Authors:  D P Pollock; J P Kutzko; E Birck-Wilson; J L Williams; Y Echelard; H M Meade
Journal:  J Immunol Methods       Date:  1999-12-10       Impact factor: 2.303

8.  Monoclonal antibodies from humans with Mycobacterium tuberculosis exposure or latent infection recognize distinct arabinomannan epitopes.

Authors:  Elise Ishida; Devin T Corrigan; Ryan J Malonis; Daniel Hofmann; Tingting Chen; Anita G Amin; Delphi Chatterjee; Maju Joe; Todd L Lowary; Jonathan R Lai; Jacqueline M Achkar
Journal:  Commun Biol       Date:  2021-10-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.